- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS Cohort B) for metastatic malignant melanoma -
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
Globe Newswire - Tue May 10, 2022 Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here